Cogent's (COGT) Bezuclastinib Up For Approval in 2026 - Stifel
Tweet Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $40.00 price target on Cogent (NASDAQ: COGT).The analyst commented, "This weekend ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


